Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9NYR9

UPID:
KBRS2_HUMAN

ALTERNATIVE NAMES:
I-kappa-B-interacting Ras-like protein 2

ALTERNATIVE UPACC:
Q9NYR9; A6NCZ5; B3KNN0; B4DNM3; Q6PK52; Q96KC7; Q9NSX1

BACKGROUND:
The NF-kappa-B inhibitor-interacting Ras-like protein 2, alternatively named I-kappa-B-interacting Ras-like protein 2, is a potent regulator of NF-kappa-B activity. It prevents the degradation of the NF-kappa-B inhibitor beta (NFKBIB) against most signals, contributing to the resistance of NFKBIB to degradation. The protein potentially blocks the phosphorylation of NFKBIB and the nuclear localization of the NF-kappa-B subunit p65/RELA. The exact role of this protein as a GTPase is unclear, but it is known that both its GTP- and GDP-bound forms can block the phosphorylation of NFKBIB.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of NF-kappa-B inhibitor-interacting Ras-like protein 2 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.